Arca Biopharma Financial Statements From 2010 to 2022

ABIO
 Stock
  

USD 2.06  0.08  3.74%   

Arca Biopharma financial statements provide useful quarterly and yearly information to potential Arca Biopharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Arca Biopharma financial statements helps investors assess Arca Biopharma's valuation, profitability, and current liquidity needs.
Arca Biopharma does not presently have any fundamental signals for analysis.
.
  
Check Arca Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arca Biopharma main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Arca Biopharma financial statements analysis is a perfect complement when working with Arca Biopharma Valuation or Volatility modules. It can also supplement Arca Biopharma's financial leverage analysis and stock options assessment as well as various Arca Biopharma Technical models . Please continue to the analysis of Arca Biopharma Correlation against competitors.

Arca Biopharma Price to Book Analysis

Arca Biopharma's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
P/B 
 = 
MV Per Share 
BV Per Share 
More About Price to Book | All Equity Analysis

Current Arca Biopharma Price to Book

    
  0.44 X  
Most of Arca Biopharma's fundamental indicators, such as Price to Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arca Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Compare to competition

Based on the latest financial disclosure, the price to book indicator of Arca Biopharma is roughly 0.44 times. This is 98.29% lower than that of the Healthcare sector and 92.72% lower than that of the Biotechnology industry. The price to book for all United States stocks is 95.37% higher than that of the company.

Arca Biopharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Arca Biopharma's current stock value. Our valuation model uses many indicators to compare Arca Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arca Biopharma competition to find correlations between indicators driving Arca Biopharma's intrinsic value. More Info.
Arca Biopharma is number one stock in cash and equivalents category among related companies. It is number one stock in shares owned by institutions category among related companies . The ratio of Cash and Equivalents to Shares Owned by Institutions for Arca Biopharma is about  1,566,912 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Arca Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Arca Biopharma's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arca Biopharma's earnings, one of the primary drivers of an investment's value.

About Arca Biopharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Arca Biopharma income statement, its balance sheet, and the statement of cash flows. Arca Biopharma investors use historical funamental indicators, such as Arca Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Arca Biopharma investors may use each financial statement separately, they are all related. The changes in Arca Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Arca Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Arca Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Arca Biopharma. Please read more on our technical analysis and fundamental analysis pages.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Arca Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Earnings Calls Now

   

Earnings Calls

Check upcoming earnings announcements updated hourly across public exchanges
All  Next Launch Module

Pair Trading with Arca Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arca Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arca Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Arca Biopharma

+0.82INTCIntel Corp TrendingPairCorr
+0.86VZVerizon Communications TrendingPairCorr
The ability to find closely correlated positions to Arca Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arca Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arca Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arca Biopharma to buy it.
The correlation of Arca Biopharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arca Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arca Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arca Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to the analysis of Arca Biopharma Correlation against competitors. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for analysis

When running Arca Biopharma price analysis, check to measure Arca Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arca Biopharma is operating at the current time. Most of Arca Biopharma's value examination focuses on studying past and present price action to predict the probability of Arca Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arca Biopharma's price. Additionally, you may evaluate how the addition of Arca Biopharma to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Arca Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arca Biopharma. If investors know Arca Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arca Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arca Biopharma is measured differently than its book value, which is the value of Arca Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Arca Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arca Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arca Biopharma's market value can be influenced by many factors that don't directly affect Arca Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arca Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arca Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arca Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.